BioTheryX Announces $35 Million Series D Financing
Current TAP Partner
SAN DIEGO, CA, July 28, 2020 — BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation to treat difficult diseases, today announced it has closed a $35 million Series D financing. The round was led by MSD Partners, L.P. In addition to general corporate development purposes, proceeds from the financing will be used to accelerate the timeline of the BTX-A51 Phase 1 clinical trial through the addition of clinical sites beyond Memorial Sloan-Kettering Cancer Center, continue IND-enabling studies for therapeutic candidates utilizing both PHMs™ and PHM®-based PROTACs (proteolysis targeting chimeras), and support more rapid development of the Company’s pre-clinical pipeline.
Louis J. DeGennaro, Ph.D., President and CEO, The Leukemia & Lymphoma Society (LLS), and BioTheryX Board Member, stated, “LLS has been pioneering breakthrough blood cancer research since 1949, and through innovative initiatives like our Therapy Acceleration Program® (TAP) we’re doing more than any cancer nonprofit to advance cutting-edge research and cures. As the first equity investment made through TAP, I am pleased to see BioTheryX’s continued progress on promising approaches to treat blood cancers that may make meaningful differences in patients’ lives.”